Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus.
Beckers, Albert; Abs, R.; van der Auwera, B.et al.
1992 • In Journal of Clinical Endocrinology and Metabolism, 75 (2), p. 564-70
[en] A 63-year-old female presented with the extremely rare occurrence of an aldosterone-secreting adrenocortical adenoma as part of the syndrome of multiple endocrine neoplasia type 1 (MEN1). Only two other MEN1 patients were reported in the literature with hyperaldosteronism. The patient's MEN1 syndrome consisted of the association of primary hyperparathyroidism due to parathyroid adenoma, a prolactinoma, and a toxic multinodular goiter. Elevated basal and meal-stimulated serum PP levels without demonstrable pancreatic tumor were also found. Genetic analysis of the aldosterone-secreting adenoma with DNA markers localized on chromosome 11 showed loss of heterozygosity in tumor DNA. Since the MEN1 syndrome is caused by loss of the tumor suppressor gene on chromosome 11 in the 11q13 region, it is probable that the same mechanism is associated with the formation of the adrenocortical adenoma.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Abs, R.
van der Auwera, B.
Willems, P. J.
Kovacs, K.
Reznik, Michel ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus.
Publication date :
August 1992
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Brandi ML, Marx SJ, Aurbach GD, Fitzpatrick LA. 1987 Familial multiple endocrine neoplasia type I: a new look at pathophysiology. EndocrRev. 8:391-405.
Croisier JC, Azerod E, Lubetski J. 1971 L'Adenomatose polyen-docrinienne (syndrome de Wermer). A propos d'une observation personnelle et revue de la litterature. Semin Hop Paris. 47:494-525.
Larsson C, Skogseid B, Öberg K, Nakamura Y, Nordenskjöld M. 1988 Multiple endocrine neoplasia type I maps to chromosome 11 and is lost in insulinoma. Nature. 332:85-7.
Thakker RV, Bouloux P, Wooding C, et al. 1989 Association of parathyroid tumors in multiple endocrine neoplasia type I with losses of alleles on chromosome 11. N Engl J Med. 321:218-24.
Friedman E, Sakaguchi K, Bale AE, et al. 1989 Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I. N Engl J Med. 321:213-8.
Yoshimoto K, Iizuka M, Iwahana H, et al. 1989 Loss of the same alleles of HRAS1 and D11S151 in two independent pancreatic cancers from a patient with multiple endocrine neoplasia type I. Cancer Res. 49:2716-21.
Radford DM, Ashley SW, Wells Jr SA, Gerhard DS. 1990 Loss of heterozygosity of markers on chromosome 11 in tumors from patients with multiple endocrine neoplasia syndrome type I. Cancer Res. 50:6529-33.
Byström C, Larsson C, Blomberg C, et al. 1990 Localization of the MEN1 gene to a small region within chromosome 1 lql3 by deletion mapping in tumors. Proc Natl Acad Sei USA. 87:1968-72.
Bale AE, Norton JA, Wong EL, et al. 1991 Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type I. Cancer Res. 51:1154-7.
Beckers A, Stevenaert A, Pirens G, Flandroy P, Sulon J, Hennen G. 1990 Cyclical Cushing's disease and its successful control under sodium valproate. J Endocrinol Invest. 13:923-9.
Beckers A, Abs R, Mahler Ch, et al. 1991 Thyrotropin-secreting pituitary adenomas: report of seven cases. J Clin Endocrinol Metab. 72:477-83.
Skogseid B, Öberg K, Benson L, et al. 1987 A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type I syndrome: five years experience. J Clin Endocrinol Metab. 64:123-340.
Hales CN, Randle PJ. 1963 Immunoassay of insulin with insulin antibody precipitate. Biochem J. 88:137-46.
Luyckx AS. 1972 Immunoassay for glucagon, ln: Lefébvre PJ, Unger RH, eds. Glucagon: molecular physiology and clinical and therapeutic implications. Oxford: Pergamon Press; pp 285-98.
Janssens J, Hellemans J, Adrian TE, et al. 1982 Pancreatic polypeptide is not involved in the regulation of the migratory motor complex in man. Regul Peptides. 3:41-9.
Noseda A, Peeters TL, Delhaye M, et al. 1987 Increased plasma motilin concentrations in small cell carcinoma of the lung. Thorax. 42:784-9.
Peeters TL, Depraetere Y, Vantrappen GR. 1981 Radioimmunoassay for somatostatin using a simple extraction method. Clin Chem. 27:888-91.
Peeters TL, Vantrappen GR, Janssens J. 1980 Fasting plasma motilin levels are related to the interdigestive motility complex. Gastroenterology. 79:716-9.
Sambrook J, Fritsch EF, Maniatis T. 1989 Molecular cloning-a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory.
Sager R. 1989 Tumor suppressor genes: the puzzle and the promise. Science. 246:1406-12.
Milner ECB, Lotshaw CL, Willems Dijk Charmley P, Con-cannon P, Schroeder HW. 1989 Isolation and mapping of a polymorphic DNA sequence pH30 on chromosome 4 (HGM provisional no. 194S139). Nucleid Acids Res. 17:4002.
Strauch G, Vallotton MB, Touitou Y, Bricaire H. 1972 The reninangiotensin-aldosterone system in normotensive and hypertensive patients with acromegaly. N Engl J Med. 287:795-9.
Herd GW. 1984 A case of primary hyperparathyroidism, primary hyperaldosteronism, and Cushing's disease. Acta Endocrinol (Co-penh). 107:371-4.
Madhavan T, Frame B, Block MA. 1970 Influence of surgical correction of primary hyperparathyroidism on associated hypertension. Arch Surg. 100:212-4.
Fertig A, Webley M, Lynn JA. 1980 Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad Med J. 56:45-7.
Heilman DE, Kartchner M, Komar N, Mayes D, Pitt M. 1980 Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 244:1351-3.
Ferris JB, Brown JJ, Cumming AMM, et al. 1983 Primary hyperparathyroidism associated with primary hyperaldosteronism. Acta Endocrinol (Copenh). 103:365-70.
Holland OB, Gomez-Sanchez CE, Kem DC, Weinberger MH, Kramer NJ, Higgins JR. 1977 Evidence against prolactin stimulation of aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin-producing pituitary microadenoma. J Clin Endocrinol Metab. 45:1064-76.
Doumith R, de Gennes JL, Cabane JP, Zygelman N. 1982 Pituitary prolactinoma, adrenal aldosterone-producing adenomas, gastric schwannoma, and colonic polyadenomas: a possible variant of multiple endocrine neoplasia (MEN) type I. Acta Endocrinol (Copenh). 100:189-95.
Gieshoff B, Benker G, Windeck R, Reinwein D. 1987 Prolaktinom und Hyperaldosteronismus bei einen 55jährigen mann: Variante der multiplen endokrinen adenomatöse (MEA) typ I? Med Klin. 82:3949.
Dluhy RG, Williams GH. 1969 Primary aldosteronism in a hypertensive acromegalic patient. J Clin Endocrinol Metab. 29:1319—24.
Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. 1973 Control of plasma aldosteronism in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab. 37:765-75.
Bravo EL, Tarazi MD, Dustan HP, et al. 1983 The changing clinical spectrum of primary aldosteronism. Am J Med. 74:641-51.
Fraser R, Baretta-Piccoli C, Brown JJ, et al. 1981 Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome, and non-tumorous hyperaldosteronism. Hypertension. 3(Suppl 1):187—92.
Grimelius L, Akerstrom G, Johansson H, Juhlin C, Rastad J. 1991 The parathyroid glands. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Boston: Blackwell; pp 375-95.
Knudson AG. 1971 Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sei USA. 68:820-3.
Friedman E, Bale AE, Marx SJ, et al. 1990 Genetic abnormalities in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 71:293—7.
Klibanski A. 1990 Editorial: further evidence for a somatic theory in the pathogenesis of human pituitary tumors. J Clin Endocrinol Metab. 7L1415A-C.
Hayward NK, Little MH, Mortimer RH, Clouston WM, Smith PJ. 1988 Generation of homozygosity at the c-Ha-ras-1 locus on chromosome lip in an adrenal adenoma from an adult with Wiede-mann-Beckwith syndrome. Cancer Genet Cytogenet. 30:127-32.
Henry I, Grandjouan S, Couillin P, et al. 1989 Tumor-specific loss of llpl5.5 alleles in delllpl3 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sei USA. 86:3247-51.
Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK. 1985 Loss of heterozygosity in three embryonal tumours suggests a common pathogenic mechanism. Nature. 316:330-4.
Fearon ER, Vogelstein B. 1990 A genetic model for colorectal tumorigenesis. Cell. 61:759-67.
Meera Khan P, Tops CMJ, van den Broeck M, et al. 1988 Close linkage of a highly polymorphic marker (195β7) to familial adenomatous polyposis (FAP) and confirmation of FAP localization on chromosome 5q21-q22. Hum Genet. 79:183-5
